JP2017043632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017043632A5 JP2017043632A5 JP2016225290A JP2016225290A JP2017043632A5 JP 2017043632 A5 JP2017043632 A5 JP 2017043632A5 JP 2016225290 A JP2016225290 A JP 2016225290A JP 2016225290 A JP2016225290 A JP 2016225290A JP 2017043632 A5 JP2017043632 A5 JP 2017043632A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- factor
- inhibitor
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 2
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000010100 anticoagulation Effects 0.000 claims 2
- 229960003886 apixaban Drugs 0.000 claims 2
- 229950011103 betrixaban Drugs 0.000 claims 2
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 229960000622 edoxaban Drugs 0.000 claims 2
- 229960000610 enoxaparin Drugs 0.000 claims 2
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical group O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 2
- 229960001318 fondaparinux Drugs 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 239000003055 low molecular weight heparin Substances 0.000 claims 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 2
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 claims 2
- -1 rNAPc2 Proteins 0.000 claims 2
- 229960001148 rivaroxaban Drugs 0.000 claims 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 claims 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- QQBKAVAGLMGMHI-WIYYLYMNSA-N eribaxaban Chemical compound N1([C@H](C[C@H](C1)OC)C(=O)NC=1C(=CC(=CC=1)N1C(C=CC=C1)=O)F)C(=O)NC1=CC=C(Cl)C=C1 QQBKAVAGLMGMHI-WIYYLYMNSA-N 0.000 claims 1
- 229940087051 fragmin Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97634307P | 2007-09-28 | 2007-09-28 | |
| US60/976,343 | 2007-09-28 | ||
| US9057408P | 2008-08-20 | 2008-08-20 | |
| US61/090,574 | 2008-08-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014166333A Division JP6047127B2 (ja) | 2007-09-28 | 2014-08-19 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018033229A Division JP2018100290A (ja) | 2007-09-28 | 2018-02-27 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017043632A JP2017043632A (ja) | 2017-03-02 |
| JP2017043632A5 true JP2017043632A5 (cg-RX-API-DMAC7.html) | 2017-07-27 |
| JP6300885B2 JP6300885B2 (ja) | 2018-03-28 |
Family
ID=40481812
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527220A Active JP5637561B2 (ja) | 2007-09-28 | 2008-09-26 | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 |
| JP2014166333A Active JP6047127B2 (ja) | 2007-09-28 | 2014-08-19 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2016225290A Active JP6300885B2 (ja) | 2007-09-28 | 2016-11-18 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2018033229A Pending JP2018100290A (ja) | 2007-09-28 | 2018-02-27 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2020042919A Pending JP2020109113A (ja) | 2007-09-28 | 2020-03-12 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2022121451A Pending JP2022153574A (ja) | 2007-09-28 | 2022-07-29 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2025008426A Pending JP2025063249A (ja) | 2007-09-28 | 2025-01-21 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527220A Active JP5637561B2 (ja) | 2007-09-28 | 2008-09-26 | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 |
| JP2014166333A Active JP6047127B2 (ja) | 2007-09-28 | 2014-08-19 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018033229A Pending JP2018100290A (ja) | 2007-09-28 | 2018-02-27 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2020042919A Pending JP2020109113A (ja) | 2007-09-28 | 2020-03-12 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2022121451A Pending JP2022153574A (ja) | 2007-09-28 | 2022-07-29 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
| JP2025008426A Pending JP2025063249A (ja) | 2007-09-28 | 2025-01-21 | 第Ｘａ因子阻害剤に対する抗体およびその使用の方法 |
Country Status (26)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| NZ572418A (en) | 2006-05-05 | 2011-08-26 | Millennium Pharm Inc | Factor xa inhibitors |
| DK2915564T3 (da) * | 2007-09-28 | 2021-02-08 | Alexion Pharma Inc | Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf |
| JP5709316B2 (ja) * | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
| CN104984319B (zh) * | 2008-12-19 | 2025-05-09 | 武田药品工业株式会社 | Tfpi抑制剂和使用方法 |
| WO2010117729A1 (en) * | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| ES2620421T3 (es) * | 2009-10-30 | 2017-06-28 | Senova Gesellschaft für Biowissenschaft und Technik mbH | Peptidasas acopladas a polímero |
| CN102762550B (zh) | 2009-12-17 | 2015-04-01 | 米伦纽姆医药公司 | Xa因子抑制剂的盐和结晶形式 |
| US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP3146977B1 (en) | 2010-03-19 | 2024-05-08 | Takeda Pharmaceutical Company Limited | Tfpi inhibitors and methods of use |
| AR082804A1 (es) | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Formas cristalinas de un inhibidor del factor xa |
| AR082803A1 (es) * | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
| CN103619883A (zh) | 2011-01-19 | 2014-03-05 | 拜耳知识产权有限责任公司 | 凝血因子抑制剂的结合蛋白 |
| FR2972114B1 (fr) * | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EA201301090A1 (ru) | 2011-03-30 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Антидоты антикоагулянтов |
| AU2012315516B2 (en) * | 2011-09-30 | 2017-05-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
| WO2013082210A1 (en) * | 2011-11-29 | 2013-06-06 | Perosphere Inc. | Anticoagulant reversal agents |
| WO2013123087A1 (en) | 2012-02-14 | 2013-08-22 | Portola Pharmaceuticals, Inc. | Process for making recombinant antidote to factor xa inhibitor |
| EP2814503A1 (en) * | 2012-02-16 | 2014-12-24 | Portola Pharmaceuticals, Inc. | MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE |
| KR102263685B1 (ko) | 2012-03-21 | 2021-06-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Tfpi 저해제 및 사용 방법 |
| JP6261093B2 (ja) * | 2012-06-14 | 2018-01-17 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 組み換え第Ｘａ因子誘導体の精製のための方法 |
| MX365612B (es) * | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| FR3000895B1 (fr) * | 2013-01-11 | 2017-02-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques |
| US20150352194A1 (en) * | 2013-01-24 | 2015-12-10 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| HK1215196A1 (zh) * | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| FR3007410B1 (fr) * | 2013-06-21 | 2016-05-27 | Lab Francais Du Fractionnement | Facteur x depourvu de domaine gla |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| CA2928762A1 (en) * | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
| PT3149163T (pt) * | 2014-05-26 | 2020-09-03 | Academisch Ziekenhuis Leiden | Proteínas proemostáticas para o tratamento de hemorragia |
| WO2016019145A1 (en) * | 2014-07-31 | 2016-02-04 | Haemonetics Corporation | Detection and classification of an anticoagulant using a clotting assay |
| WO2016028872A2 (en) | 2014-08-19 | 2016-02-25 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor ix function |
| CA2961739C (en) | 2014-08-20 | 2024-04-30 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
| CN105030703B (zh) * | 2015-06-23 | 2018-03-23 | 上海旭东海普药业有限公司 | 一种防治疗栓塞性疾病的利伐沙班片及其制备方法 |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| US20190046450A1 (en) | 2016-02-24 | 2019-02-14 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
| KR20180123062A (ko) * | 2016-02-29 | 2018-11-14 | 이리디아, 인크. | 정보 저장을 위한 방법, 조성물, 및 장치 |
| US10859562B2 (en) | 2016-02-29 | 2020-12-08 | Iridia, Inc. | Methods, compositions, and devices for information storage |
| US10640822B2 (en) | 2016-02-29 | 2020-05-05 | Iridia, Inc. | Systems and methods for writing, reading, and controlling data stored in a polymer |
| US10438662B2 (en) | 2016-02-29 | 2019-10-08 | Iridia, Inc. | Methods, compositions, and devices for information storage |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| PE20190661A1 (es) | 2016-06-17 | 2019-05-08 | Portola Pharm Inc | Preparacion de derivados del factor xa |
| WO2018115235A1 (en) | 2016-12-22 | 2018-06-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antidotes to anti-coagulant drugs allowing diagnosis and treatment |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| EP3672520A4 (en) * | 2017-08-21 | 2021-06-30 | Allele Biotechnology And Pharmaceuticals, Inc. | LIGHT ABSORBING COMPOSITIONS AND METHODS OF USE |
| ES3050257T3 (en) | 2017-11-15 | 2025-12-19 | Novo Nordisk As | Factor x binders enhancing fx activation |
| US12195774B2 (en) | 2018-06-19 | 2025-01-14 | Alexion Pharmaceuticals, Inc. | Antidotes to factor XA inhibitors |
| CN112261935A (zh) * | 2018-08-14 | 2021-01-22 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
| US20220125894A1 (en) * | 2019-02-07 | 2022-04-28 | Alexion Pharmaceuticals, Inc. | Methods for treating intracranial hemorrhage and assessing efficacy |
| US11655465B1 (en) | 2019-05-02 | 2023-05-23 | Iridia, Inc. | Enzymes and systems for synthesizing DNA |
| PL4010379T3 (pl) | 2019-08-08 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Kompozycje i sposoby wytwarzania czynnika xa i pochodnych |
| EP4164755A4 (en) * | 2020-06-16 | 2024-12-04 | Alexion Pharmaceuticals, Inc. | METHODS FOR TESTING THE POWER OF ANDEXANET |
| US11837302B1 (en) | 2020-08-07 | 2023-12-05 | Iridia, Inc. | Systems and methods for writing and reading data stored in a polymer using nano-channels |
| US12073926B2 (en) | 2020-09-21 | 2024-08-27 | Instrumentation Laboratory Company | Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample |
| CN113484386B (zh) * | 2021-05-21 | 2024-02-13 | 郑州轻工业大学 | 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法 |
| CN114681597A (zh) * | 2022-03-11 | 2022-07-01 | 兆科药业（合肥）有限公司 | 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用 |
| CN116327627B (zh) * | 2023-03-10 | 2024-06-07 | 四川大学 | 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH596313A5 (cg-RX-API-DMAC7.html) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
| US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5278144A (en) * | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
| US5597799A (en) * | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AU1570292A (en) | 1991-02-07 | 1992-09-07 | Board Of Trustees Of The University Of Illinois, The | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| RU2136311C1 (ru) | 1991-09-13 | 1999-09-10 | Чирон Корпорейшн | Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор |
| WO1993009804A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| US6117836A (en) | 1992-03-20 | 2000-09-12 | Cor Therapeutics, Inc. | Glycosylation-mediated inhibition of factor X |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| DE4430205A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| AT404357B (de) * | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| SE9604744D0 (sv) * | 1996-12-20 | 1996-12-20 | Pharmacia & Upjohn Ab | A modified coagulation agent |
| AT405517B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AU6673898A (en) * | 1997-03-07 | 1998-09-22 | Washington University | Factor x variant |
| JPH1149800A (ja) * | 1997-06-05 | 1999-02-23 | Fujimori Kogyo Kk | アンヒドロトロンビンの合成方法 |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| AU3629800A (en) * | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| US6258559B1 (en) | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US6858599B2 (en) | 1999-06-30 | 2005-02-22 | Mochida Pharmaceutical Co., Ltd. | Tricyclic compound having spiro union |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| EP1095933A1 (en) * | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| ES2254385T3 (es) * | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US6660885B2 (en) * | 2000-03-13 | 2003-12-09 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
| CA2419979A1 (en) | 2000-09-08 | 2002-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
| US7070740B1 (en) | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
| US20030064414A1 (en) * | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
| US7138506B2 (en) | 2001-05-09 | 2006-11-21 | Genetic Id, Na, Inc. | Universal microarray system |
| US6989267B2 (en) | 2001-07-02 | 2006-01-24 | Agilent Technologies, Inc. | Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films |
| DE10155075A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Cyclische Sulfonamide |
| US6861236B2 (en) | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
| US20040198660A1 (en) * | 2002-11-06 | 2004-10-07 | Petersen Lars Christian | Tissue factor antagonist and protein C polypeptide compositions |
| US7247654B2 (en) * | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| WO2005088310A2 (en) | 2004-03-05 | 2005-09-22 | The Scripps Research Institute | High throughput glycan microarrays |
| JP4441336B2 (ja) | 2004-06-11 | 2010-03-31 | 日本碍子株式会社 | マイクロアレイの製造方法 |
| US9223929B2 (en) | 2005-03-14 | 2015-12-29 | The California Institute Of Technology | Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays |
| US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
| WO2006102687A1 (en) | 2005-03-22 | 2006-09-28 | The Trustees Of Columbia University In The City Of New York | A liposome-based microarray and methods of use thereof |
| ATE549317T1 (de) * | 2005-11-08 | 2012-03-15 | Millennium Pharm Inc | Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer |
| US20070111322A1 (en) | 2005-11-15 | 2007-05-17 | Lin-Cheng Yang | Novel method of using inject printing for creating microarrays |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| DK2915564T3 (da) * | 2007-09-28 | 2021-02-08 | Alexion Pharma Inc | Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf |
| JP5709316B2 (ja) | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| WO2010117729A1 (en) * | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
-
2008
- 2008-09-26 DK DK14197779.3T patent/DK2915564T3/da active
- 2008-09-26 EP EP20198287.3A patent/EP3824902A1/en not_active Withdrawn
- 2008-09-26 PT PT141977793T patent/PT2915564T/pt unknown
- 2008-09-26 SG SG2012072716A patent/SG185263A1/en unknown
- 2008-09-26 PT PT161675343T patent/PT3078743T/pt unknown
- 2008-09-26 MX MX2010003095A patent/MX2010003095A/es active IP Right Grant
- 2008-09-26 JP JP2010527220A patent/JP5637561B2/ja active Active
- 2008-09-26 CA CA2697583A patent/CA2697583C/en active Active
- 2008-09-26 LT LTEP16167534.3T patent/LT3078743T/lt unknown
- 2008-09-26 HU HUE08834136A patent/HUE031647T2/en unknown
- 2008-09-26 EP EP14197779.3A patent/EP2915564B1/en active Active
- 2008-09-26 HR HRP20161255TT patent/HRP20161255T1/hr unknown
- 2008-09-26 PT PT88341367T patent/PT2193196T/pt unknown
- 2008-09-26 SI SI200831678A patent/SI2193196T1/sl unknown
- 2008-09-26 SI SI200832130T patent/SI3078743T1/sl unknown
- 2008-09-26 PL PL14197779T patent/PL2915564T3/pl unknown
- 2008-09-26 CN CN201310301566.3A patent/CN103446579B/zh active Active
- 2008-09-26 US US12/239,651 patent/US8153590B2/en active Active
- 2008-09-26 KR KR1020107008718A patent/KR101698214B1/ko active Active
- 2008-09-26 BR BR122022001846-7A patent/BR122022001846B1/pt active IP Right Grant
- 2008-09-26 ES ES08834136.7T patent/ES2597436T3/es active Active
- 2008-09-26 KR KR1020177023761A patent/KR20170100071A/ko not_active Ceased
- 2008-09-26 WO PCT/US2008/078014 patent/WO2009042962A2/en not_active Ceased
- 2008-09-26 CN CN201110447251.0A patent/CN102559644B/zh active Active
- 2008-09-26 SI SI200832153T patent/SI2915564T1/sl unknown
- 2008-09-26 NZ NZ583944A patent/NZ583944A/en unknown
- 2008-09-26 PL PL16167534T patent/PL3078743T3/pl unknown
- 2008-09-26 PL PL08834136T patent/PL2193196T3/pl unknown
- 2008-09-26 DK DK16167534.3T patent/DK3078743T3/da active
- 2008-09-26 HU HUE14197779A patent/HUE052423T2/hu unknown
- 2008-09-26 HU HUE16167534A patent/HUE050063T2/hu unknown
- 2008-09-26 BR BRPI0816837-7A patent/BRPI0816837B1/pt active IP Right Grant
- 2008-09-26 ES ES16167534T patent/ES2796623T3/es active Active
- 2008-09-26 DK DK08834136.7T patent/DK2193196T3/en active
- 2008-09-26 EP EP16167534.3A patent/EP3078743B1/en active Active
- 2008-09-26 AU AU2008304192A patent/AU2008304192B9/en active Active
- 2008-09-26 CN CN2011104472050A patent/CN102533702A/zh active Pending
- 2008-09-26 CN CN2008801079738A patent/CN101802188B/zh active Active
- 2008-09-26 KR KR1020207001549A patent/KR102271404B1/ko active Active
- 2008-09-26 ES ES14197779T patent/ES2849426T3/es active Active
- 2008-09-26 KR KR1020167003860A patent/KR102069498B1/ko active Active
- 2008-09-26 EP EP08834136.7A patent/EP2193196B1/en active Active
- 2008-09-26 LT LTEP08834136.7T patent/LT2193196T/lt unknown
-
2010
- 2010-02-16 IL IL203993A patent/IL203993A/en active IP Right Grant
- 2010-03-23 ZA ZA2010/02039A patent/ZA201002039B/en unknown
-
2012
- 2012-03-07 US US13/414,499 patent/US8455441B2/en active Active
-
2013
- 2013-04-11 AU AU2013205326A patent/AU2013205326A1/en not_active Abandoned
- 2013-05-07 US US13/889,014 patent/US9062298B2/en active Active
- 2013-06-11 US US13/915,525 patent/US8889129B2/en active Active
-
2014
- 2014-07-21 US US14/337,074 patent/US9388401B2/en active Active
- 2014-08-07 AU AU2014210620A patent/AU2014210620B2/en active Active
- 2014-08-19 JP JP2014166333A patent/JP6047127B2/ja active Active
- 2014-09-04 ZA ZA2014/06514A patent/ZA201406514B/en unknown
-
2016
- 2016-06-08 US US15/176,461 patent/US10675335B2/en active Active
- 2016-10-12 CY CY20161101020T patent/CY1118482T1/el unknown
- 2016-11-18 JP JP2016225290A patent/JP6300885B2/ja active Active
-
2017
- 2017-01-12 AU AU2017200212A patent/AU2017200212A1/en not_active Abandoned
- 2017-11-02 IL IL255397A patent/IL255397B/en active IP Right Grant
-
2018
- 2018-02-27 JP JP2018033229A patent/JP2018100290A/ja active Pending
-
2019
- 2019-02-18 IL IL264886A patent/IL264886B/en active IP Right Grant
- 2019-06-13 AU AU2019204123A patent/AU2019204123A1/en not_active Abandoned
- 2019-11-08 NO NO2019040C patent/NO2019040I1/no unknown
-
2020
- 2020-02-26 IL IL272926A patent/IL272926A/en unknown
- 2020-03-12 JP JP2020042919A patent/JP2020109113A/ja active Pending
- 2020-05-07 US US16/869,117 patent/US11839646B2/en active Active
- 2020-07-08 HR HRP20201071TT patent/HRP20201071T1/hr unknown
- 2020-08-04 CY CY20201100715T patent/CY1123504T1/el unknown
- 2020-09-09 NL NL301063C patent/NL301063I2/nl unknown
- 2020-09-23 FR FR20C1045C patent/FR20C1045I2/fr active Active
- 2020-09-23 NO NO2020033C patent/NO2020033I1/no unknown
- 2020-12-16 CY CY2020042C patent/CY2020042I2/el unknown
- 2020-12-22 HU HUS2000057C patent/HUS2000057I1/hu unknown
- 2020-12-22 LT LTPA2020540C patent/LTC3078743I2/lt unknown
-
2021
- 2021-08-17 AU AU2021218033A patent/AU2021218033A1/en not_active Abandoned
-
2022
- 2022-07-29 JP JP2022121451A patent/JP2022153574A/ja active Pending
-
2023
- 2023-11-02 US US18/500,675 patent/US20240082367A1/en active Pending
-
2024
- 2024-12-20 AU AU2024287094A patent/AU2024287094A1/en active Pending
-
2025
- 2025-01-21 JP JP2025008426A patent/JP2025063249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017043632A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201071T1 (hr) | Protuotrovi za inhibitore faktora xa i postupci njihove uporabe | |
| FI3604510T3 (fi) | Vastalääkkeitä tekijä xa:n estäjille ja menetelmiä niiden käyttämiseksi | |
| Warkentin | Bivalent direct thrombin inhibitors: hirudin and bivalirudin | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2019194251A5 (cg-RX-API-DMAC7.html) | ||
| Kurihara et al. | Endothelin: a potent vasoconstrictor associated with coronary vasospasm | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2015518818A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509624A5 (cg-RX-API-DMAC7.html) | ||
| JP2010539945A5 (ja) | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 | |
| Gould et al. | Recent advances in the discovery and development of direct coagulation factor Xa inhibitors | |
| JP2015536943A5 (cg-RX-API-DMAC7.html) | ||
| JP2012533552A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506727A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533910A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508771A5 (cg-RX-API-DMAC7.html) | ||
| JP2017532365A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525704A5 (cg-RX-API-DMAC7.html) | ||
| Fouad | Chronic hepatitis C-associated thrombocytopenia: aetiology and management | |
| Comerota et al. | A comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| SI2576524T1 (en) | USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR | |
| JP2015514115A5 (cg-RX-API-DMAC7.html) | ||
| Ettingshausen et al. | The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? |